首页> Gut: Journal of the British Society of Gastroenterology> Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab

导出原文传递

翻译打印收藏纠错

第一作者： Nicholas A Kennedy

作者： Nicholas A Kennedy ^[1] ; James R Goodhand ^[2] ; Claire Bewshea ^[3] ; Rachel Nice ^[4] ; Desmond Chee ^[5] ; Simeng Lin ^[6] ; Neil Chanchlani ^[7] ; Jeffrey Butterworth ^[8] ; Rachel Cooney ^[9] ; Nicholas M Croft ; Ailsa L Hart ; Peter M Irving ; Klaartje B Kok ; Christopher A Lamb ; Jimmy K Limdi ; Jonathan Macdonald ; Dermot PB McGovern ; Shameer J Mehta ; Charles D Murray ; Kamal V Patel ; Richard CG Pollok ; Timothy Raine ; Richard K Russell ; Christian P Selinger ; Philip J Smith ; Jack Bowden ; Timothy J McDonald ; Charlie W Lees ; Shaji Sebastian ; Nicholas Powell ; Tariq Ahmad

作者单位： Department of Gastroenterology, Queen Elizabeth University Hospital ^[1] Exeter Inflammatory Bowel Disease and Pharmacogenetics Research Group ^[2] Division of Digestive Diseases, Faculty of Medicine ^[3] Department of Paediatric Gastroenterology ^[4] Department of Gastroenterology ^[5] Centre for Immunobiology, Blizard Institute ^[6] Medical School ^[7] F. Widjaja Foundation Inflammatory Bowel and Immunology Research Institute ^[8] Department of Biochemistry, Exeter Clinical Laboratory International ^[9]

关键词 inflammatory bowel disease autoimmune disease COVID-19 inflammatory diseases infliximab vedoluzimab clarity

发布时间 2021-07-09

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交